Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
180
Trial Sponsor
Clinical Trial Start Date
April 22, 2022
0Primary Completion Date
May 2, 2023
0Study Completion Date
2025
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
ARO-ANG 3 Injection0
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)0
Last Updated
August 22, 2023
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
None (Open Label)0
Study summary
Participants with documented homozygous familial hypercholesterolemia (HoFH) who have provided informed consent will receive 2 open-label doses of ARO-ANG3 and be evaluated for safety and efficacy parameters through 36 weeks. Participants who complete the first 36 week treatment period may opt to continue in an additional 24-month extension period during which they will receive up to 8 doses open-label doses of ARO-ANG3.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
